OTC Regulatory & Market Alerts

The FDA advisory panel unanimously determined oral phenylephrine is not an effective nasal decongestant at OTC doses. The ruling is now propagating through retail SKU rationalisation and brand reformulation decisions. An estimated $1.8B in US PE-containing cold and flu SKUs are affected. Brands must choose: reformulate with pseudoephedrine (behind-counter friction), switch to nasal delivery formats, or exit the category. Retailers are beginning to flag PE products. Client action required immediately — reformulation timelines are 18–24 months.

The American Dental Association and British Dental Association have both issued formal negative statements on charcoal-based oral care products. The primary concern is enamel abrasivity. No charcoal toothpaste has achieved the ADA Seal of Acceptance. The whitening claims made by most charcoal products are not substantiated by clinical evidence. Brands still selling charcoal toothpaste as a mainstream product carry regulatory and reputational risk. Advise clients to exit or reposition this format.

The CARES Act established an administrative order process replacing the slower notice-and-comment rulemaking for OTC monograph changes. This creates a faster pathway for ingredient approvals, reformulations, and new indications. Watch the FDA OTC monograph docket for new administrative orders in H2 2026. Brands with pending formulation changes should engage FDA proactively through the new process.

FDA has not established a regulatory framework for OTC topical CBD products. State-level rules vary significantly. Brands marketing topical CBD with pain relief or anti-inflammatory claims are operating in a grey zone. Structural/function claim framing reduces risk but does not eliminate it. Monitor FDA administrative guidance and state enforcement actions. Build the claim architecture to survive scrutiny in any eventual federal framework.

Unlike prescription medicines, OTC products are not subject to a centralised EU approval process. National competent authorities apply differing standards for the same actives and indications. Brands seeking pan-European OTC distribution must navigate multiple national filings. This creates asymmetric competitive advantage for brands with established national authorisations. Brands planning EU expansion should prioritise high-volume markets (Germany, France, Italy) as regulatory anchors.

As phenylephrine exits and pseudoephedrine remains the only evidenced oral decongestant, the Combat Methamphetamine Epidemic Act purchase limits and ID requirements are now the category's primary friction point. Innovation is moving to nasal spray formats (oxymetazoline, xylometazoline) and combination products that reduce the need for systemic decongestants. Brands building nasal spray SKU architecture now will capture the reformulation-driven market shift.

GLP-1 medication users report a consistent cluster of GI side effects: nausea, constipation, bloating, and reflux. No major OTC manufacturer has launched a purpose-built companion product. The claim architecture is defensible using existing monograph actives (simethicone, bismuth subsalicylate, psyllium, ginger). The branded opportunity combines OTC legitimacy, a large and growing addressable user base, and a gap in pharmacy shelf architecture. First-mover brand equity will be significant. Move in 2026; by 2027 this will be crowded.

Opill (norgestrel 0.075mg) approval in 2023 established that complex Rx products can achieve OTC status. Migraine treatments (triptans) and additional contraceptive formulations are now in active FDA review. Brands adjacent to these therapeutic categories should build consumer education infrastructure now — before switch approval — to capitalise on the moment of category opening. Healthcare professional engagement strategy and consumer DTC readiness are the two execution levers.

Retailer private label OTC is capturing significant share in analgesics, antacids, and cold/flu. The only sustainable defence for branded OTC products is clinical differentiation that private label cannot credibly replicate: proprietary formulations, superior delivery systems (extended release, liquid-filled capsule, nasal spray), or a specific sub-indication claim with unique evidence. Advise branded OTC clients to invest in at least one defensible scientific differentiator before next product cycle.